[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eosinophilic-esophagitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eosinophilic-esophagitis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,45,58,86,124,147,168,196,217,243,269,294,317,341,363,386,407,431,455,483,503,527,547,568,591],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054223","the-esophageal-string-test-as-a-diagnostic-screening-tool-for-eosinophilic-esophagitis-among-africans-with-dysphagia-in-mali-and-the-united-states-100054223",false,"NCT07027826","The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States","Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Able to provide informed consent.\n2. Aged 18 to 65 years.\n3. Born in the African continent or their parents were born in Africa,\n4. Exhibiting symptoms of dysphagia and\u002For prior history of food impaction.\n5. Undergoing clinically indicated endoscopy at the NIH Clinical Center (U.S.), Centre Hospitalier Universitaire Gabriel Tour(SqrRoot)(Copyright) (Mali), or other local clinics (Mali) and willing to provide research samples and data.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Recent steroid use (systemic or swallowed\u002Ftopical corticosteroid) within 4 weeks prior to endoscopy.\n2. Recent use of dupilumab (Dupixent) within the last 6 months.\n3. Recent use of other biologic medications (within either 6 months or 5 half-lives, whichever is longer). Examples of biologic medications include:\n\n3a. mepolizumab (Nucala)\n\n3b. reslizumab (Cinqair, Cinqaero)\n\n3c. benralizumab (Fasenra)\n\n3d. cendakimab\n\n3e. tezepelumab (Tezspire)\n\n3f. barzolvolimab\n\n4\\. Individuals suffering from a bleeding diathesis (e.g., hemophilia, severe thrombocytopenia).\n\n5\\. Current use of anticoagulant medications.\n\n6\\. Pregnancy.\n\n7\\. Treatment with another investigational drug or other investigational intervention within 6 months or 5 half-lives whichever is longer.\n\n8\\. Individuals with a known history of any of the following:\n\n8a. eosinophilic esophagitis\n\n8b. esophageal stricture unable to be passed with an upper endoscope\n\n8c. esophageal cancer\n\n8d. esophageal motility disorder (e.g., achalasia)\n\n8e. esophageal varices\n\n8f. esophageal or gastric surgery including fundoplication\n\n8g. neurologic cause of dysphagia (e.g., stroke, Parkinson s disease, etc.)\n\n8h. allergy to gelatin\n\n8i. inability to swallow pills\n\n9\\. Any condition that, in the investigator s opinion, places the individual at undue risk by participating in the study.\n\nCo-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the principal investigator in consultation with the medical monitor. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.","ALL","18 Years","65 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background:\n\nEosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the tube that moves food from the mouth to the stomach. Diagnosing EoE currently requires a specialized tool called an endoscope. The esophageal string test (EST) is another test; the EST collects fluid from the upper digestive tract. An EST is simpler and cheaper than an endoscopy. Researchers want to know if an EST can diagnose EoE.\n\nObjective:\n\nTo test if the EST can diagnose EoE in people who have trouble swallowing.\n\nEligibility:\n\nAdults aged 18 to 65 years with trouble swallowing. They must have been born in the African continent or their parents were born in Africa.\n\nDesign:\n\nParticipants will be screened. They will give blood, stool, urine, and skin swab samples. They will complete surveys about their medical history, diet, symptoms, and home environment. They will bring a sample of their drinking water for testing.\n\nParticipants will have an EST. They will swallow a pill capsule that contains a nylon string. One end of the string will be taped to their cheek. The string will unravel down the esophagus and into the stomach. It will be pulled out after 1 hour. Fluids that soaked into the string will be tested.\n\nAt a different visit, participants will have an endoscopic exam. An endoscope is a flexible tube that is inserted down the mouth; it can be used to take tissue samples from the esophagus, stomach, and small intestine.\n\nParticipants will have a final visit in person, online, or by phone. They will take a survey and talk about their test results.",[28,29],"Dysphagia","Eosinophilic Esophagitis",[29,28,31],"Esophageal string test","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":22},"2026-07-16",{"date":40,"type":22},"2027-08-31",{"name":42,"class":43},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",3,{"id":46,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":47,"targetDuration":4,"studyType":23,"phases":48,"briefSummary":26,"conditions":49,"keywords":50,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":57,"locationsCount":44},"100595082",{"count":21,"type":22},[25],[28,29],[29,28,31],"2026-07-01",{"date":53,"type":36},"2026-07-02",{"date":55,"type":22},"2026-07-07",{"date":40,"type":22},{"name":42,"class":43},{"id":59,"slug":60,"hasResults":12,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100247843","natural-history-and-genetics-of-food-allergy-and-related-conditions-100247843","NCT02504853","Natural History and Genetics of Food Allergy and Related Conditions","* GENERAL INCLUSION CRITERIA:\n\nAll participants must meet the following criteria:\n\n1. Be 2 to 99 years-old at the time of enrollment for participants who will be seen at the NIH CC; be 0 (newborn) to 99 years-old at the time of enrollment for participants who will submit mail-in samples or participate in telehealth visits. Only viable neonates will be enrolled.\n2. Willing to allow storage of blood, buccal swabs, saliva, nasal swabs, stool samples, and other clinically appropriate tissue specimens for future use in medical research\n3. Required to have a primary care or other physician who will manage all health conditions related or unrelated to the study objectives\n\nADDITIONAL INCLUSION CRITERIA FOR AFFECTED PARTICIPANTS\n\nIn addition to the general criteria listed above, affected participants must meet 1 of the following criteria:\n\n1. Have a clinical history of an immediate hypersensitivity reaction to food(s) and be sensitized to food allergen(s) (as evidenced by positive SPT or allergen-specific IgE testing)\n2. Be sensitized (as evidenced by positive SPT or allergen-specific IgE testing) to food allergen(s) but have no overt clinical history of IgE-mediated symptoms when they eat that food(s)\n3. Have a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs)\n4. Have a diagnosis of eosinophilic esophagitis (EoE), or clinical suspicion for EoE as determined by the principal investigator (PI) or associate investigators (AIs)\n5. Have a history of atopic dermatitis based on self-report or physician assessment.\n\nADDITIONAL INCLUSION CRITERIA FOR UNAFFECTED RELATIVES:\n\nIn addition to the general criteria listed above, unaffected relatives must meet the following criteria:\n\n1. Be a relative of an affected participant\n2. Be unaffected by food allergy (as determined by clinical history and\u002For allergy testing) or be unaffected by the genetic condition under study\n\nADDITIONAL INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS\n\nIn addition to the general criteria listed above, healthy volunteers must meet the following criteria:\n\n1. Be unrelated to an affected participant\n2. Be unaffected by food allergy (as determined by clinical history and\u002For allergy testing) or be unaffected by the genetic condition under study\n\nADDITIONAL PROCEDURE- SPECIFIC INCLUSION CRITERIA:\n\nThe following additional inclusion criteria apply for participants undergoing leukapheresis:\n\n1. Age \\>= 18 years\n2. Stable hematologic parameters (definition: white blood cell count \\> 2,500\u002FmicroL, hemoglobin \\> 10 g\u002FdL, and platelet count \\> 75,000\u002FmicroL)\n\nGENERAL EXCLUSION CRITERIA:\n\nParticipants will be excluded for any of the following:\n\n* Presence of conditions that, in the judgment of the investigator or the referring physician, may put the participant at undue risk or make them unsuitable for participation in the study.\n* Inability to participate for the duration of the study.\n* The PI deems that participation in the study would not be expected to advance the study goals.\n\nADDITIONAL PROCEDURE- SPECIFIC EXCLUSION CRITERIA\n\nAdditional exclusion criteria apply for unaffected relatives and healthy volunteers who are undergoing endoscopy with biopsies for research purposes. Unaffected relatives and healthy volunteers will be excluded from participating in this procedure if they meet any of the following criteria:\n\n1. uncontrolled asthma or Grade 3 or higher by the American Society of Anesthesiologist s Physical Status Classification System (https:\u002F\u002Fjournals.lww.com\u002Fanesthesiologyopen\u002Ffulltext\u002F2026\u002F04000\u002Famerican\\_society\\_of\\_anesthesiologists\\_statement\\_on.2.aspx)\n2. history of adverse reaction to conscious sedation or general anesthesia required for endoscopy\n3. hemoglobin \\\u003C 11 g\u002FdL\n4. platelet count \\\u003C 100,000 microL\n5. PT INR \\>1.3 or PTT prolonged by \\> 3 seconds\n6. pregnant or breastfeeding\n7. viral screens positive for HIV or hepatitis B or C\n8. severe unstable myocardial ischemia or cardiomyopathy\n9. severe hypoxemia due to chronic pulmonary disease\n10. recent abdominal surgery\n11. anticoagulant therapy that cannot be interrupted\n12. history of reflux disease within the last 3 years or use of acid-suppression medication (including over-the-counter medications such as Tums, Rolaids, Zantac, Prilosec OTC, or Prevacid OTC) within the last 2 months\n13. chronic GI or immunologic disease\n14. clinically indicated EGD or colonoscopy within the past 12 months\n15. use of systemic or inhaled corticosteroids within the past 4 months\n16. have a history of EGID including EoE\n17. younger than 18 years of age",true,"1 Day","99 Years",{"count":68,"type":22},1800,"OBSERVATIONAL","Background:\n\n\\- About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them.\n\nObjective:\n\n\\- To learn more about the causes and effects of food allergy and related conditions.\n\nEligibility:\n\n* People ages 2 99 who have food allergy and\u002For a related genetic or other condition\n* Their relatives\n* Healthy relatives and volunteers\n\nDesign:\n\n* Participants will have at least 3 visits over 1 2 years, and then once a year for up to 12 years. Each may last a day or longer.\n* Participants will be screened with medical history, physical exam, and questionnaires.\n* Participants may have the following:\n* Blood tests\n* Allergy skin prick tests: Drops of allergens are placed on the back or arm. The skin is scratched under each drop.\n* Leukapheresis: blood is taken from a needle in one arm, passed through a machine, and returned through a needle in the other arm.\n* X-rays\n* Esophageal string test: One end of a string is taped to the cheek and the other end is packed into a capsule. When the capsule is swallowed, the string unwinds; it is left in for at least 1 hour.\n* EGD and colonoscopy: Biopsies are taken from the gastrointestinal system.\n* Tiny biopsies of skin\n* Photographs of the body\n* Collection of cells through:\n* Swab of nose, inside of cheek, or skin\n* Gentle skin scrape\n* Tape stripping: piece of tape is put on the skin and pulled off.",[72,73,74,29],"Food Allergy","Loeys-Dietz Syndrome","Atopic Dermatitis",[29,73,74,76,77],"TGFbeta","Natural History","2026-06-30",{"date":51,"type":36},{"date":81,"type":36},"2015-07-29",{"date":83,"type":22},"2027-06-15",{"name":42,"class":43},1,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":95,"studyType":69,"phases":4,"briefSummary":96,"conditions":97,"keywords":106,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":85},"100401388","indiana-university-gastrointestinal-motility-diagnosis-registry-100401388","NCT04506593","Indiana University Gastrointestinal Motility Diagnosis Registry","Gastrointestinal Motility Diagnosis Registry","Inclusion Criteria:\n\n1. Patients who presented to the GI outpatient clinics, in-patient consult service, and outpatient endoscopy centers within the Division of Gastroenterology and Hepatology\n2. Carries a diagnosis of GI motility disorder based on the diagnostic criteria listed in table\n\nExclusion Criteria:\n\n1\\. Coexisting medical conditions that may limiting participation in clinical research trial",{"count":94,"type":22},5000,"10 Years","Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders",[29,98,99,100,101,102,103,104,105],"Gastroesophageal Reflux Disease (GERD)","Gastroparesis","Functional Vomiting","Irritable Bowel Syndrome (IBS)","Constipation","Chronic Intestinal Pseudo-obstruction","Fecal Incontinence","Small Intestinal Bacterial Overgrowth",[107,108,109,110,111,112,113,99],"Eosinophilic esophagitis","Chronic intestinal pseudo-obstruction","Small Bowel dysmotility","SIBO","Vomiting","Functional dyspepsia","Functional bloating","2026-06-15",{"date":116,"type":36},"2026-06-16",{"date":118,"type":36},"2014-11-01",{"date":120,"type":22},"2026-11",{"name":122,"class":123},"Indiana University","OTHER",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":65,"studyType":69,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":146},"100590801","prevalence-and-description-of-fire-food-induced-immediate-response-of-the-esophagus-in-the-pediatric-population-with-eosinophilic-esophagitis-100590801","NCT06972147","Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis","FIREO","Inclusion Criteria:\n\n* Patients over 6 and under 18 years of age at the time of inclusion\n* Follow-up in the allergology unit of Angers University Hospital for eosinophilic esophagitis\n\nExclusion Criteria:\n\n* Patients or legal representative with severe communication or language comprehension difficulties\n* Patients or legal representatives objecting to study participation","6 Years","17 Years",{"count":134,"type":22},40,"A new clinical entity of eosinophilic esophagitis, Food Induced Immediate Response of the Esophagus or FIRE, has been described since 2020. Diagnostic criteria are not clearly established. Specific questioning is necessary for differential diagnosis, such as the oro-pharyngeal syndrome notably described in pollinics, or a mechanical blockage strictly speaking linked to esophagitis. The aim is to obtain epidemiological data on this entity.",[29],"2026-06-12",{"date":114,"type":36},{"date":140,"type":36},"2025-07-01",{"date":142,"type":22},"2026-08-01",{"name":144,"class":145},"University Hospital, Angers","OTHER_GOV",2,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":19,"enrollmentInfo":155,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":85},"100361033","characteristics-and-inflammatory-markers-in-children-with-eosinophilic-esophagitis-eoe-100361033","NCT03980886","Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)","EoE","Inclusion Criteria:\n\n* Have a known EoE diagnosis\n* Complain of dysphagia, vomiting, or abdominal pain, especially if recalcitrant to acid blocking therapy (but does not have to be recalcitrant to acid blocking medications)\n* Present with food impaction\n* Present with esophageal stricture\n* Have characteristic endoscopic findings of EoE of pallor, linear furrows, lichenification, white plaques, or concentric rings\n\nExclusion Criteria:\n\n* None","1 Year",{"count":156,"type":22},1500,"Single center observational and specimen banking study for children with eosinophilic esophagitis EoE to gauge natural history and inflammatory markers",[29],"2026-06-02",{"date":161,"type":36},"2026-06-04",{"date":163,"type":36},"2019-02-11",{"date":165,"type":22},"2028-12-17",{"name":167,"class":123},"University of California, San Diego",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":146},"100639754","phase-2-a-trial-of-upadacitinib-for-non-responsive-eosinophilic-esophagitis-100639754","NCT07588568","A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis","A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (ATUNE)","ATUNE","Inclusion Criteria:\n\n1. Age 18-65 years.\n2. Diagnosis of EoE per 2018 AGREE consensus guidelines.\n3. Currently using topical corticosteroids (TCS) for EoE treatment (either swallowed budesonide, ≥2mg total daily dose or swallowed fluticasone, ≥1760 mcg total daily dose) for at least 8 weeks (prior to the screening endoscopy) and willing to remain on the same TCS treatment with no changes to regimen throughout the study.\n4. Have active esophageal eosinophilia (peak eosinophil count ≥15 eos\u002Fhpf \\[eosinophils per high power field\\]) as measured during the screening endoscopy despite ongoing therapy with TCS.\n5. Have active symptoms of esophageal dysfunction attributed to EoE (such as trouble swallowing, heartburn, reflux, vomiting, chest pain, painful swallowing, abdominal pain, malnutrition, etc.) in the 4 weeks prior to the screening endoscopy.\n6. Willing to continue all current EoE treatments (including medications such as proton pump inhibitors (PPIs), diet elimination, etc.) throughout participation in the study.\n7. Able to read, comprehend, and sign consent form.\n8. Ability to take oral medication (swallow a pill) and be willing to adhere to the study regimen (follow dosing instructions and complete study procedures).\n\nExclusion Criteria:\n\n1. Use of systemic corticosteroids (such as prednisone or methylprednisolone) within 4 weeks of the screening endoscopy.\n2. Use of dupilumab (dupixent) within 3 months of the screening endoscopy.\n3. Use of estrogen (including estrogen-containing contraceptives and other hormonal treatments) within 30 days of screening.\n4. Previous esophageal resection.\n5. Medical instability making it unsafe to perform an upper endoscopy.\n6. At the Screening \u002F Baseline or Enrollment Visit, meeting any of the following conditions:\n\n   6.1. Two or more prior episodes of herpes zoster (shingles), or one or more episodes of disseminated herpes zoster;\n\n   6.2. One or more prior episodes of disseminated herpes simplex (including eczema herpeticum);\n\n   6.3. Human immunodeficiency virus (HIV) infection, defined as confirmed positive anti-HIV antibody (HIV Ab) test or a positive HIV Ab\u002FAg test;\n\n   6.4. Active tuberculosis (TB) or latent TB, or meet TB exclusionary parameters;\n\n   6.5. Active infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days, or oral\u002Fintramuscular anti-infectives within 14 days prior to the visit;\n\n   6.6. Active diverticulitis within the past 3 months;\n\n   6.7. Chronic recurring infection and\u002For active viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study;\n\n   6.8. COVID-19 infection: In participants who tested positive for COVID-19, at least 5 days must have passed between a COVID-19 positive test result and the visit of asymptomatic participants. Participants with mild\u002Fmoderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics (fever reducers such as ibuprofen, aspirin, and paracetamol) for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Participants may be rescreened if deemed appropriate by the investigator based upon the participant's health status.\n\n   6.9. Hepatitis B (HBV) and Hepatitis C (HCV) screening values that meet the following criteria at the most recent testing prior to the first dose of study drug:\n\n   6.9.1. HBV: hepatitis B surface antigen (HBs Ag) positive (+) test or detectable HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for participants who are hepatitis B core antibody (HBc Ab) positive (+);\n\n   6.9.2. HCV: detectable HCV ribonucleic acid (RNA) in any participant with anti-HCV antibody (HCV Ab).\n7. At the Screening \u002F Baseline or Enrollment visit, any of the following medical diseases or disorders:\n\n   7.1. Prior history of\n   * cerebrovascular accident (stroke),\n   * myocardial infarction (heart attack),\n   * coronary stenting,\n   * coronary bypass surgery (heart bypass surgery),\n   * or thrombotic events including deep venous thrombosis (DVT) and pulmonary embolism (PE);\n\n   7.2. History of an organ transplant which requires continued immunosuppression;\n\n   7.3. History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and\u002For other products in the same class;\n\n   7.4. History of GI perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment;\n\n   7.5. Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; participants with a history of gastric banding\u002Fsegmentation (such as Lap Band or Realize Band) are not excluded;\n\n   7.6. History of malignancy except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix;\n\n   7.7. Current uncontrolled hypertension defined as a confirmed systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg;\n\n   7.8. Known inherited or acquired conditions that predispose to hypercoagulability;\n\n   7.9. Current or past smokers;\n\n   7.10. In patients 50 years of age and older:\n   * High-density lipoprotein (HDL) cholesterol level of \\\u003C40mg per deciliter,\n   * Diabetes mellitus,\n   * Family history of premature coronary heart disease,\n   * Extraarticular rheumatoid arthritis.\n\n   7.11. Severe hepatic impairment (i.e., Child Pugh C cirrhosis).\n8. Participants of child-bearing potential who do not meet the following:\n\n   8.1. Participants must not have a positive serum pregnancy test (blood test) at the Screening Visit and must have a negative urine pregnancy test at the Enrollment visit prior to the first dose of study drug.\n\n   8.2. Participants with an abnormal or inconclusive serum pregnancy test at Screening must have absence of clinical suspicion of pregnancy or other pathological causes and a serum pregnancy test ≥ 3 days later to document continued lack of a positive result.\n\n   8.3. Participants with a urine pregnancy test at the Enrollment visit that is borderline or ambiguous must have a serum pregnancy test performed. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n\n   8.4. Participants of childbearing potential who are not able and\u002For willing to practice at least 1 protocol-specified method of birth control that is highly effective throughout participation in the study (from Screening through at least 30 days after the last dose of study drug. Use of estrogen-containing contraception is not allowable. Participants of non-childbearing potential do not need to use birth control.\n9. Participants who are pregnant, breastfeeding, or considering becoming pregnant during the study and for 30 days after the last dose of study drug.\n10. Participants who received treatment with any investigational drug of chemical or biologic nature within 30 days or five half-lives (whichever is longer) prior to the screening endoscopy or who are currently enrolled in another interventional clinical study.\n11. Participants with systemic use of known strong cytochrome P450 3A (CYP3A) inhibitors or strong CYP3A inducers within 30 days or five half-lives (whichever is longer) of the screening endoscopy through the end of study participation: Herbal therapies and other traditional medicines with unknown effect on CYP3A taken systemically are prohibited within 30 days prior to the screening endoscopy and throughout the study. Herbal therapies and other traditional medicines are defined as any herbal formulation intended to treat or prevent health problems and may include supplements based on which herbs the participant is taking.\n12. Participants who have received any live vaccine with replicating potential within 30 days prior to the first dose of study drug or have expected need of vaccination with any live vaccine with replicating potential during study participation including at least 30 days after the last dose of study drug. Live vaccines that are incapable of replicating are permitted.\n13. Screening laboratory values that meet the following criteria at the most recent testing prior to the first dose of study drug:\n\n    13.1. Serum aspartate transaminase (AST) \\> 2 × upper limit of normal (ULN); 13.2. Serum alanine transaminase (ALT) \\> 2 × ULN; 13.3. Estimated glomerular filtration rate (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \\\u003C 30 mL\u002Fmin\u002F1.73 m2; 13.4. Total white blood cell (WBC) count \\\u003C 2,500\u002FµL; 13.5. Absolute neutrophil count (ANC) \\\u003C 1,200\u002FµL; 13.6. Platelet count \\\u003C 100,000\u002FµL; 13.7. Absolute lymphocyte count \\\u003C 750\u002FµL; 13.8. Hemoglobin \\\u003C 9 g\u002FdL.\n14. Known allergic reaction, significant sensitivity, or intolerance to Janus kinase (JAK) inhibitors or their components\n15. History of or current clinically significant medical or psychiatric conditions or any other reason that in the opinion of the Investigator would interfere with the participant's participation in this study, would place the participant at risk by participating in the study or would make the participant an unsuitable candidate to receive study drug.\n16. Inability to read or understand English.",{"count":177,"type":22},52,[179],"PHASE2","The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE).\n\nThe main question it aims to answer are:\n\n\\- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity?\n\nParticipants will:\n\n* Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib\n* Fill out surveys and answer health questions\n* Visit the clinic every 4 weeks for checkups and tests",[152,29,182],"Eosinophilic Esophagitis (EoE)",[29,152,184,185],"upadacitinib","rinvoq","NOT_YET_RECRUITING","2026-05-06",{"date":189,"type":36},"2026-05-15",{"date":191,"type":22},"2026-07",{"date":193,"type":22},"2030-06",{"name":195,"class":123},"University of North Carolina, Chapel Hill",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":202,"maxAge":18,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":85},"100545385","pediatric-eosinophilic-esophagitis-pedeoe-effect-of-allergen-heat-denaturation-on-eoe-remission-a-pilot-trial-100545385","NCT06381219","Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot Trial","Inclusion Criteria:\n\nAll children (aged 12 months and older) presenting (since 1-1-2014: moment of diagnostic guideline standardization for pedEoE) with diagnosed pedEoE at UZ Leuven eliminating either hen's egg or cow's milk or both and in complete remission after their latest biopsy (no longer than 12 months earlier, but preferentially as short as possible after their latest biopsy) are eligible for the study. If the last biopsy has been performed more than 12 months earlier, a new gastro-duodenoscopy will be performed to verify remission and rule out e.g. active gastritis. If they are on PPI and\u002For local budesonide treatment, this should be stable for at least 3 months and will remain untouched during the entire study. We will include 18 pedEoE subjects suffering from cow's milk induced EoE and 18 suffering from hen's egg induced EoE.\n\nExclusion Criteria:\n\n* Children younger than 12 months\n* Children with active pedEoE\n* Children who refuse to adhere to the protocol\n* Children with associated IgE mediated hen's egg and\u002For cow's milk allergy with specific IgE antibody titers that predict active (baked egg and\u002For baked milk) food allergy with cut-off titers as used at the consultation of allergy (KLL). Those children will become eligible however if their titers decrease while the study is still open.","12 Months",{"count":204,"type":22},36,[25],"The objective of the study is to study whether the introduction of heated food products (more specifically heated hen's egg and\u002For cow's milk) in children with EoE would be possible without re-occurrence of the eosinophilic inflammation, while the intake of less heated products might cause disease recidive. Moreover, we would like to study whether the gradual re-introduction of less heated products after the most heated form is tolerated, could lead to tolerance induction in EoE.",[29],"2026-05-04",{"date":210,"type":36},"2026-05-05",{"date":212,"type":36},"2023-12-19",{"date":214,"type":22},"2028-12-31",{"name":216,"class":123},"Universitaire Ziekenhuizen KU Leuven",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":242},"100561906","phase-3-once-daily-versus-twice-daily-budesonide-orodispersible-tablets-for-induction-of-remission-in-eoe-100561906","NCT06596252","Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE","Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 mg Once Daily vs. 1 mg Twice Daily Budesonide Orodispersible Tablets in Adults With Eosinophilic Esophagitis","EOS-4","Inclusion Criteria:\n\n* Signed informed consent,\n* Male or female patients, 18 to 75 years of age,\n* Confirmed clinico-pathological diagnosis of eosinophilic esophagitis (EoE) according to established diagnostic criteria\n* Active symptomatic and histological EoE\n* Negative pregnancy test in females of childbearing potential at baseline visit.\n\nExclusion Criteria:\n\n* Clinical and endoscopic signs of gastroesophageal reflux disease (GERD),\n* Achalasia, scleroderma esophagus, or systemic sclerosis,\n* Other clinically evident causes than EoE for esophageal eosinophilia,\n* Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection \\[candida esophagitis\\]),\n* Any relevant systemic disease (e.g., AIDS, active tuberculosis, hepatitis B or C),\n* If careful medical monitoring is not ensured: cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection,\n* Liver cirrhosis or portal hypertension,\n* History of cancer in the last five years,\n* History of esophageal surgery at any time or of esophageal dilation procedures within the last 4 weeks prior to screening visit, or need for an immediate endoscopic intervention due to a stricture\n* Upper gastrointestinal bleeding within 8 weeks prior to baseline visit,\n* Existing or intended pregnancy or breast-feeding.","75 Years",{"count":227,"type":22},308,[229],"PHASE3","The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.",[29],"2026-04-22",{"date":234,"type":36},"2026-04-27",{"date":236,"type":36},"2021-05-21",{"date":238,"type":22},"2027-03",{"name":240,"class":241},"Dr. Falk Pharma GmbH","INDUSTRY",26,{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":64,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":95,"studyType":69,"phases":4,"briefSummary":252,"conditions":253,"keywords":258,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":85},"100631904","prospective-registry-of-esophageal-motility-100631904","NCT07506746","PRospective Registry of Esophageal Motility","PREM","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study.\n2. The procedures are the standard of care for the patient or the participant is taking the medicinal product according to clinical practice\n3. Aged \\> 18 years.\n4. Any typical (heartburn or regurgitation) or atypical reflux symptom (Laryngeal Cough, laryngitis, sub-glottic stenosis, globus, laryngeal cancer, vocal cord granuloma, vocal cord irritation, vocal cord polyps and post-nasal drip; Oropharyngeal: Dental erosion, pharyngitis, sore or burning throat, gingivitis and halitosis; Ears and sinuses: Earaches, otitis media and sinusitis; Pulmonary: Chronic bronchitis, pneumonia, aspiration, bronchiectasis, asthma and idiopathic pulmonary fibrosis; Cardiac: Arrhythmia, angina and myocardial infarction; Sleep: Sleep apnoea, sleep deprivation, insomnia, snoring, nightmare and sleep disturbance), but also any obstructive esophageal symptom potentially reflecting a primary or secondary motility disorder (oropharyngeal or esophageal dysphagia, chest pain, bolus impaction). Every patient with a diagnosis of esophageal inflammatory disorder (including EoE and others) or systemic rheumatological condition (scleroderma, systemic sclerosis, lichen planus and others), every patient previously undergone to any anti-reflux surgery, bariatric surgery, endoscopic or surgical esophageal or gastric myotomy (also for gastroparesis) may be included.\n5. Patients must be referred to the Digestive Physiopathology Unit of IRCCS San Raffaele Hospital for motility tests\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Not willing to provide informed consent to the inclusion in the registry",{"count":251,"type":22},10000,"Digestive physiopathology is a branch of gastroenterology aiming to study patients with upper GI symptoms, mainly gastro-esophageal, potentially indicating the presence of Gastroesophageal Reflux Disease (GERD)\u002FBarrett Esophagus (BE) or obstructive esophageal motility disorders (achalasia being the most relevant), but including also other primary motility disorders such as Esophgago-Gastric Junction Outflow Obstruction (EGJOO), Hypercontractile Esophagus (HE), Distal Esophageal Spasm (DES) and other minor disorders. Physiopathological testing encompasses High-Resolution Manometry (HRM), 24-H esophageal pH-impedance testing, Functional Lumen Imaging Probe (FLIP) assessment. All these tests are designed to provide a clear phenotyping of esophago-gastric disorders related to reflux or obstructive esophageal symptoms, either in naïve patients, as well as after foregut surgery (particularly anti-reflux surgery, achalasia\u002Fprimary motility disorders treatment).",[254,255,29,256,257],"Esophageal Diseases","Achalasia","Motility Disorder","GERD",[259],"Esophageal disease; manometry; FLIP, pH-impedance","2026-03-28",{"date":262,"type":36},"2026-04-02",{"date":264,"type":36},"2026-03-09",{"date":266,"type":22},"2041-03",{"name":268,"class":123},"IRCCS San Raffaele",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":85},"100578893","patient-centered-decision-support-for-eosinophilic-esophagitis-100578893","NCT06817213","Patient-Centered Decision Support for Eosinophilic Esophagitis","Patient-Centered Decision Support for Eosinophilic Esophagitis: A Pilot Study","Inclusion Criteria:\n\n* New EoE patient evaluations ≥18 years old at University of Michigan (UM) that have an upcoming outpatient visit in a UM-gastroenterology or allergy \\& immunology clinic,\n* Able to speak and read English.\n\nExclusion Criteria:\n\n* Prisoners and institutionalized individuals due to logistical limitations for use of a web app and follow-up interactions in these populations.\n* Patients that have significant cognitive or visual impairment that limits interaction with the decision aid (DA)\n* Patients that are terminally ill\n* Patients that do not have an email address or reliable access to the internet",{"count":134,"type":22},[25],"The study team is conducting this project to learn more about how patients with eosinophilic esophagitis (EoE) like to use and receive educational materials about treatment options and treatment decision making.\n\nThis study will assess the efficacy of a decision support intervention to make decisions about treatment and disease management for patients with EoE and will assess the feasibility and acceptability of the intervention to inform future R01-level studies.\n\nThe study team hypothesize that deploying the intervention will be feasible, and it will demonstrate high acceptability among EoE patients. Additionally, that patients that use the intervention (vs general education about EoE) will report greater treatment knowledge, increased readiness to choose a therapy, adherence to therapy, and follow-up.",[29],[281,282,283,284],"tailored educational materials","general educational materials","online surveys","decision aid","2026-03-25",{"date":287,"type":36},"2026-03-31",{"date":289,"type":36},"2025-04-16",{"date":291,"type":22},"2026-12",{"name":293,"class":123},"University of Michigan",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":314,"locationsCount":316},"100486023","phase-1-a-trial-to-evaluate-ep-104gi-in-adults-with-eosinophilic-esophagitis-eoe-100486023","NCT05608681","A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","A Phase 1b\u002F2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE)","RESOLVE","Inclusion Criteria:\n\n* Symptomatic EoE;\n* For women of childbearing potential, a negative pregnancy test and willing to use a highly effective method of birth control until end of study;\n* Willing and able to adhere to study-related procedures and visit schedule;\n* Willing and able to provide informed consent.\n\nCriteria for crossover to EP 104GI from vehicle control (randomized dose optimization portion):\n\n1. Has completed the randomized dose optimization portion of the trial to Week 24, inclusive\n2. Without safety concerns for receiving EP 104GI ie, does not meet exclusion criteria or have other safety issue\n\nExclusion Criteria:\n\n* Concomitant esophageal disease, relevant GI disease, or any condition, history, or laboratory abnormality that might interfere with the study;\n* Oral or esophageal mucosal infection of any type (bacterial, viral, or fungal);\n* Oropharyngeal or dental conditions that prevents normal eating;\n* Severe esophageal motility disorders other than EoE;\n* Contraindication to or factors that substantially increase risks associated with EGD or biopsy, or narrowing of the esophagus that precludes EGD with a standard 9-10 mm endoscope, stricture requiring dilation within 8 weeks prior to Screening, or the need for dilation prior to EGD at Baseline;\n* Any condition for which the use of corticosteroids is contraindicated (Participants with well controlled non-insulin dependent diabetes are permitted);\n* Active or quiescent systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Or recent use of IV or oral antibiotics;\n* Hypersensitivity, or intolerance to corticosteroids, or to any of the ingredients in the investigational medicinal product, including carboxymethyl cellulose, and polysorbate 80, or to the ingredients in Synacthen \u002F cosyntropin (used in the ACTH stimulation test);\n* Recent use of disallowed medications, or unwillingness to not use disallowed medications during the study;\n* Recent initiation of a elimination or elemental diet (dietary therapy must remain stable throughout the study);\n* Morning serum cortisol level ≤ 5 μg\u002FdL (138 nmol\u002FL);\n* Clinically significant abnormal laboratory values;\n* Recent or currently planned participation in another interventional trial ;\n* Previous participation in this study and had received study treatment;\n* Females who are pregnant, breastfeeding, or planning to become pregnant during the study;\n* Malignancies or history of malignancy within prior 5 years, except for treated or excised non-metastatic BCC, SCC of the skin, or cervical carcinoma in situ;\n* History of alcohol or drug abuse;\n* Any other reason, that, in the Investigator's opinion, unfavorably alters participant risk, confounds results, or prevents the participant from complying with study requirements.",{"count":303,"type":22},117,[305,179],"PHASE1","A Phase 1b\u002F2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity. Approximately 27 to 33 participants will be enrolled in dose escalation: 3-6 participants per dose cohort. The number of participants enrolled in escalation will depend on the number of dose escalation cohorts evaluated, and dose cohorts needing to be expanded. An additional 10-24 participants will be enrolled in 1 or 2 cohorts of 10-12 participants each at tolerable dose regimen(s) selected based on the accumulated clinical data to identify the recommended phase 2 dose(s) (RP2D). In the Phase 2 randomized dose optimization portion of the study, approximately 120 subjects will be randomized to Dose A (120 mg total dose), Dose B (160 mg total dose), or matching vehicle control, with an overall assignment ratio of 1:1:1. The total number of participants in both portions of the study will be approximately 160. The study involves 8-10 site visits spread over approximately 52 weeks. Participants in an extended PK sub study will have up to 4 additional visits, to a maximum of 108 weeks post-dose. The participants will either receive the active study drug (EP-104GI) or matching vehicle control. Matching vehicle control will be used only in randomized dose optimization portion of the study. Participants randomized to receive vehicle control may receive EP-104GI (Dose A or Dose B) following the completion of Week 24 providing they meet eligibility criteria for crossover to EP-104GI. Participants randomized to receive EP-104GI on Day 0 will not receive EP-104GI or vehicle control at Week 24. The study drug or matching vehicle control will be administered by qualified personnel during an esophagogastroduodenoscopy (EGD) procedure at the Baseline\u002FDosing visit. Safety will be assessed throughout the study. Blood and urine samples will be collected at site visits for laboratory assessments and to measure plasma levels of EP-104GI. Participants will complete questionnaires to assess symptoms of dysphagia and odynophagia and will undergo 3-5 EGDs with esophageal biopsies at the Baseline, Week 4 (dose escalation phase only), Week 12, Week 24 (randomized dose optimization phase only), Week 26, and Week 52 (randomized dose optimization phase only).",[29],"2026-03-17",{"date":310,"type":36},"2026-03-19",{"date":312,"type":36},"2023-03-31",{"date":291,"type":22},{"name":315,"class":241},"Eupraxia Pharmaceuticals Inc.",23,{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":323,"enrollmentInfo":324,"targetDuration":326,"studyType":69,"phases":4,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":85},"100454591","eosinophilic-gastrointestinal-disorders-registry-100454591","NCT05199532","Eosinophilic Gastrointestinal Disorders Registry","Inclusion Criteria:\n\n* Patients with an established diagnosis of an EGID, based on pathology findings from an endoscopy or colonoscopy with biopsies.\n* Patients suspected of having an EGID and undergoing endoscopic evaluation for further assessment\n\nExclusion Criteria:\n\n* Patients who do not consent to participate","25 Years",{"count":325,"type":22},500,"5 Years","The purpose of this study is to learn more about Eosinophilic Gastrointestinal Disorders (EGIDs). With this registry we hope to find out more about the symptoms that patients have during their treatment, the quality of life they have with the diagnosis, what the disease looks like throughout the different treatment methods, and if there is a connection between EGIDs and connective tissue disorders.\n\nThe goal of this study is to be able to better understand EGIDs and use information gained from all the information collected on this study for more precise treatments in the future. We want to create a large collection of samples, called a biorepository, to learn the most about EGIDs as possible. When the samples are collected, which will occur at procedures directed by your child's doctor as part of their standard of care, they will be stored for an unlimited amount of time to perform experiments on these samples and to gather information about EGIDs",[29,329,330,331],"Eosinophilic Gastroenteritis","Eosinophilic Colitis","Eosinophilic Gastrointestinal Disease","2026-03-16",{"date":334,"type":36},"2026-03-18",{"date":336,"type":36},"2020-12-18",{"date":338,"type":22},"2035-12",{"name":340,"class":123},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":64,"sex":17,"minAge":349,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":85},"100569565","a-non-interventional-observational-study-to-assess-long-term-efficacy-and-safety-of-dupilumab-for-the-treatment-of-patients--12-years-with-eosinophilic-esophagitis-under-real-world-conditions-in-germany-100569565","NCT06695897","A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany","Prospective, Non-interventional Observational Study to Characterize Dupilumab in the Long-term Management of Eosinophilic Esophagitis, Safety and Patient Reported Outcomes (Quality of Life) in Clinical Routine","ProMEAL","Inclusion Criteria:\n\n* Patients diagnosed with EoE who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy\n* Patients for whom the treating physician has decided to initiate new treatment with dupilumab for EoE according to EU-SmPC independently from entry in study or for whom treatment with dupilumab for EoE according to EU-SmPC has been started within the last 7 days. The decision to initiate dupilumab treatment is made by the treating physician and the patient according to the patients' medical need and to the standard of best medical practice. This decision is made independently and before inclusion in this NIS.\n* ≥ 12 years of age at baseline visit\n* ≥ 40 kg bodyweight\n* Voluntary study participation and signed written informed consent by patient and parent(s)\u002Fguardian(s), if applicable\n\nExclusion Criteria:\n\n* Patients who have a contraindication to dupilumab according to the current EU-SmPC.\n* Patients who have been treated with dupilumab for more than 7 days\n* Any acute or chronic condition that, in the treating physician's opinion, would limit the patients' ability to complete questionnaires or to participate in this study or impact the interpretation of the results.\n* Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study (parallel inclusion in another Sanofi-independent registry might be possible if the patient gives consent)\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","12 Years",{"count":351,"type":22},150,"This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with respect to their medical history, socio-demographic and disease characteristics, comorbidities (including type 2 inflammatory and atopic conditions), concomitant therapies and prior EoE treatments. Furthermore, this NIS aims to describe the long-term effectiveness of dupilumab for the treatment of EoE as assessed by the treating physician and reported by the patient, and its effect on health-related quality of life (HRQoL) during an individual observational period of two years. In addition, data on real-world use patterns and long-term safety data of dupilumab treatment for EoE will be collected.",[29],"2026-03-04",{"date":356,"type":36},"2026-03-06",{"date":358,"type":36},"2024-12-02",{"date":360,"type":22},"2029-05-29",{"name":362,"class":241},"Sanofi",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":146},"100476532","phase-2-zemaira-eosinophilic-esophagitis-pilot-study-100476532","NCT05485155","Zemaira Eosinophilic Esophagitis Pilot Study","An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis","ZEEPS","Inclusion Criteria:\n\n1. Participant and\u002For legally authorized representative must be able to understand and provide informed consent prior to study procedures being performed.\n2. Willing and able to comply with study visits and activities\n3. Age ≥ 18 to ≤ 70 years at study enrollment\n4. Histologically active eosinophilic esophagitis (EoE) at time of screening or within 12 weeks prior to enrollment, with a peak count of ≥ 15 eosinophils (eos)\u002Fhigh powered field (hpf) in any region of the esophagus, with no other known cause for esophageal eosinophilia; involvement of eosinophilic inflammation in other gastrointestinal segments will be allowed but not required or sufficient.\n5. History of approximately 8 week standard of care (SOC) treatment (e.g., proton pump inhibitors (PPI's), topical corticosteroids) that did not adequately control or treat the EoE or documentation that such treatment was not tolerated. Participant may re-screen if this is not met.\n6. Stable medical management of EoE (and other eosinophilic disorders, if applicable) including stable dosage of medications in the 8 weeks prior to study enrollment, if applicable. Participants may be on baseline anti-EoE therapy (such as elimination diet, elemental diet, proton pump inhibitors (PPI), topical or systemic glucocorticoids (≤10 milligrams (mg) daily), immunosuppressive agents, cromolyn, and H1 and H2 anti-histamines) as long as there is agreement not to change their dosage.\n7. Willing to maintain current dietary regimen throughout the course of the study. Diet must have been stable for 8 weeks prior to baseline endoscopy.\n\nExclusion Criteria:\n\n1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol.\n2. Current active H. pylori infection. A history of H. pylori infection needs to have medical documentation of one of the three acceptable eradication tests: antigen, breath or histology. Participants with current active H. pylori infections can be re-screened for study participation in the future if they are treated and have medical documentation of one of the three acceptable eradication tests: antigen, breath or histology.\n3. Another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome\\*, Churg Strauss vasculitis, eosinophilic granuloma or a parasitic infection).\n\n   \\*Hypereosinophilic syndrome defined by multiple organ involvement (with the exception of atopic disease or eosinophilic gastrointestinal disorder (EGID)) and persistent blood absolute eosinophil count ≥1500\u002Fmicroliter.\n4. Systemic gastrointestinal disorders such as Crohn's disease, inflammatory bowel disease, or Celiac disease not including chronic gastritis, chronic duodenitis, mucosal eosinophilia or other EGID's.\n5. Diagnosed with Chronic Obstructive Pulmonary Disease (COPD).\n6. Known immunoglobulin A (IgA) deficiency (i.e., IgA level \\< 8 mg\u002FdL at screening).\n7. Current coronavirus disease of 2019 (COVID-19) infection (i.e., detection of the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) before the screening endoscopy using testing done at the clinical site).\n8. Hematological disorders that prevent the blood from clotting (e.g., hemophilia, Von Willebrand disease, clotting factor deficiencies).\n9. Currently on anti-coagulation medications (except aspirin\u002FNon-steroidal anti-inflammatory drugs).\n10. Known history of hypersensitivity following infusions of human blood or blood components (e.g., human immunoglobulins or human albumin).\n11. Known history of hypersensitivity or anaphylaxis to Zemaira or other A1AT products.\n12. Uncontrolled, or poorly controlled, comorbid conditions including, but not limited to, cardiovascular diseases, hypertension and diabetes as defined by the following criteria:\n\n    * A myocardial infarction within the last 6 months.\n    * Blood pressure \\> 179\u002F99 mmHg\n    * Diabetics with a hemoglobin A1C (HbA1C) \\> 7% and that are deemed to have uncontrolled diabetes as defined by the physician\n13. History of cancer: Individuals who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained. Individuals who have had other malignancies are eligible provided that the individual is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.\n14. Current or recent use of any investigational drug (within 3 months or 5 half-lives, whichever is longer, prior to screening).\n15. Currently participating or planning to participate in another clinical study involving an investigational drug during the course of this study.\n16. Presence of steroid-responsive diseases (e.g., asthma) with a recent (within the last 6 months) history of disease exacerbations requiring steroid treatment.\n17. Current use of systemic steroids with daily dose \\> 10 mg for any reason or steroid burst for \\> 3 days within 1 month of screening.\n18. Current pregnancy or breastfeeding.\n19. Any esophageal stricture unable to be passed with a standard, diagnostic upper endoscope.\n20. Esophageal varices or interventional treatment for esophageal varices that, in the opinion of the investigator, would put the participant at undue risk for significant complications from an endoscopy procedure.\n21. History of alcohol or drug abuse within 6 months prior to screening.\n22. Participant or his\u002Fher immediate family is a member of the investigational team.\n23. Presence of clinically significant laboratory abnormalities at the screening that meets one or more of the following criteria:\n\n    1. Serum alanine aminotransferase (ALT) ≥ 3 times upper limit of normal (ULN)\n    2. Serum total bilirubin ≥2 times ULN\n    3. Absolute neutrophil count (ANC) ≤ 1000 cells\u002Fmm3\n    4. Hemoglobin (Hgb) ≤ 10.0 g\u002FdL\n    5. Platelet count ≤ 100,000\u002Fmm3\n    6. Glomerular Filtration Rate (GFR) ≤ 44 mL\u002Fmin\u002F1.73 m2\n24. Planned or anticipated major surgical procedure during the study.\n25. Known or suspected immunodeficiency disorder, including human immunodeficiency disorder (HIV) or a history of invasive opportunistic infections (e.g., tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis, or an infectious etiology of esophagitis (e.g. cytomegalovirus or Candida) despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged infections suggesting an immune-compromised status as judged by the investigator.\n26. Planned or anticipated use of any prohibited medications and procedures during the study.\n27. Currently on Zemaira for other indications.\n28. Initiation, discontinuation or change in the dosage regimen of the following medications within 8 weeks prior to the baseline endoscopy:\n\n    Proton pump inhibitors Leukotriene inhibitors Nasal and\u002For inhaled corticosteroids Participants on a stable dose of these medications for at least 8 weeks prior to the baseline endoscopy may be included in the study. PPI and leukotriene inhibitor dosing must not change during the study, but nasal and\u002For inhaled corticosteroids can be increased if there is a deterioration in the condition for which the medications are prescribed.\n29. Presence of the following esophageal disorders: achalasia cardia, Barrett's esophagus or precancerous lesions noted on the endoscopy.\n30. Women of childbearing potential, or male participants with female partners of childbearing potential, who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 12 weeks after the last dose. Highly effective contraceptive measures include:\n\n    1. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) for one month prior to screening\n    2. Intrauterine device; intrauterine hormone-releasing system\n    3. Bilateral tubal ligation\n    4. Vasectomized partner\n    5. And\u002For sexual abstinence\n31. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.","70 Years",{"count":373,"type":22},15,[179],"This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.",[29],"2025-12-16",{"date":379,"type":36},"2025-12-17",{"date":381,"type":36},"2025-05-15",{"date":383,"type":22},"2027-01",{"name":385,"class":123},"Children's Hospital Medical Center, Cincinnati",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":393,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":146},"100309771","changes-in-esophageal-distensibility-with-proton-pump-inhibitors-in-patients-with-esophageal-eosinophilia-a-pilot-study-100309771","NCT03312686","Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study","EOE","Inclusion Criteria:\n\n1\\. Presence of eosinophilia on esophageal biopsy, defined as a peak count of \\> 15 eosinophils per high power field (HPF) on light microscopy based on biopsies from at least 2 of the 3 biopsy segments (upper, middle and distal esophagus)\n\nExclusion Criteria:\n\n1. Secondary causes of esophageal eosinophilia has been excluded, such as eosinophilic GI diseases, celiac disease, Crohn's disease, esophageal infection, hypereosinophilic syndrome, drug hypersensitivity, vasculitis, pemphigus, connective tissue diseases, graft vs. host disease\n2. Age \\\u003C 18 or \\> 65 years\n3. Contraindication for biopsy, such as presence of esophageal varices, coagulopathy\n4. History of esophageal surgery, gastric or esophageal malignancy, anatomical abnormality, or major primary motility disorder (such as achalasia)\n5. Pregnancy\n6. Prisoners",{"count":394,"type":22},10,"This pilot study will explore whether treatment of eosinophilic inflammation in the esophagus is associated with an improved distensibility of the esophagus. Furthermore, previous studies of the esophagus using EndoFlip only measured distensibility of the distal esophagus, specifically the distal esophagus and esophagogastric junction. Eosinophilia in EoE has been demonstrated to affect both upper, middle and lower esophagus. The aim is to measure distensibility both proximal and distal, before and after treatment.",[29],[398],"endoflip","2025-11-21",{"date":401,"type":36},"2025-11-24",{"date":403,"type":36},"2016-11",{"date":405,"type":22},"2026-12-31",{"name":122,"class":123},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":64,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":154,"studyType":69,"phases":4,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":85},"100610432","utility-of-mucosal-impedance-device-in-chronic-esophageal-disorders-100610432","NCT07227506","Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:","Diagnostic Utility of Mucosal Impedance Device in Patients With GERD and Chronic Esophageal Disorders:","Inclusion Criteria:\n\n1\\. Patients with chronic esophageal symptoms such as atypical or typical reflux symptoms and dysphagia, is here for upper endoscopy testing.\n\nExclusion Criteria:\n\n1. Presence of esophageal stricture\n2. Unstable patients who cannot undergo this testing.\n3. Patients on anticoagulation on the day of procedure.\n4. Presence of esophageal cancer.\n5. Pregnancy.\n6. Minor patients.",{"count":415,"type":22},50,"Background \\& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making.\n\nAim:\n\nHere, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.",[418,29],"Gerd",[420,421],"gerd","eosinophilic esophagitis","2025-11-11",{"date":424,"type":36},"2025-11-13",{"date":426,"type":22},"2025-11-20",{"date":428,"type":22},"2028-07-01",{"name":430,"class":123},"Medical College of Wisconsin",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":439,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":454},"100249239","omega-outcome-measures-in-eosinophilic-gastrointestinal-disorders-across-the-ages-100249239","NCT02523118","OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages","A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)","OMEGA","Inclusion Criteria:\n\n* Males or females 3 years of age and older\n* Mucosal eosinophilia:\n\nEoE ≥ 15 eosinophils\u002FHPF in the distal or proximal esophagus EoG ≥ 30 eosinophils\u002FHPF in 5 HPF\\'s in the body and\u002For antrum EoN ≥ 53 eosinophils\u002FHPF in the duodenum and\u002For ≥ 56 eosinophils\u002FHPF in the jejunum and\u002For ileum EoC ≥ 84 eosinophils\u002FHPF from the transverse or descending colon and\u002For ≥ 32 eosinophils\u002FHPF from the rectosigmoid colon or a biopsy from any colonic location with ≥ 100 eosinophils\u002FHPF\n\n\\- Presence of symptoms is required for patients who are newly diagnosed but not required for patients who were previously diagnosed.\n\nExclusion Criteria:\n\n* History of intestinal surgery other than G tube placement\n* Enrolled in a blinded investigational study at the time of the first study visit\n* Have esophageal stricture (\\<3mm)\n* Have other identifiable causes for eosinophilia (except Inflammatory Bowel Disease): infections, Gastrointestinal (GI) cancer, other GI inflammatory disease (e.g., Ulcerative Colitis or Crohn\\'s Disease)","3 Years",{"count":441,"type":22},1350,"The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and\u002For colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an idea how well the person is doing.",[444,29,445,329,330],"Eosinophilic Gastrointestinal Disorders (EGIDs)","Eosinophilic Gastritis","2025-09-11",{"date":448,"type":36},"2025-09-12",{"date":450,"type":36},"2015-07-17",{"date":452,"type":22},"2051-01-01",{"name":385,"class":123},19,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":463,"maxAge":132,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":85},"100545831","edn-and-eosinophilic-esophagitis-100545831","NCT06387030","EDN and Eosinophilic Esophagitis","Noninvasive Biomarkers Correlated With Esophageal Eosinophilic Infiltrate in Pediatric Patients With Eosinophilic Esophagitis","OesEDN","Inclusion Criteria:\n\n* Suspicion of eosinophilic esophagitis due to symptoms of esophageal dysfunction OR follow-up of eosinophilic esophagitis histologically proven at a previous upper GI endoscopy.\n* Indication for upper GI endoscopy for diagnosis or follow-up of eosinophilic esophagitis, or for pathology other than eosinophilic esophagitis.\n\nExclusion Criteria:\n\n\\- Patients with chronic inflammatory bowel disease, esophageal atresia or achalasia","2 Years",{"count":465,"type":22},60,[25],"Eosinophilic esophagitis is a recent and emerging chronic disease, secondary to eosinophilic infiltration of the esophageal mucosa leading to esophageal dysfunction. The diagnosis of this pathology, and monitoring of the efficacy of therapies, relies on the assessment of eosinophilic density on esophageal biopsies: follow-up requires numerous digestive endoscopies under general anesthesia, at each therapeutic change, to assess remission. The search for non-invasive biomarkers of active eosinophilic esophagitis is therefore a subject of major interest.\n\nThe first step is to study EDN (Eosinophil-Derived Neurotoxin), a protein secreted when eosinophils are activated. Several studies have investigated the association between serum EDN, EDN on esophageal brushing or esophageal biopsies with eosinophilic esophagitis activity, and the results look promising. Urinary EDN is associated with atopy but has not been studied in eosinophilic esophagitis. EDN is a biomarker of interest because it is stable over time and, above all, can be measured routinely, making it applicable to routine patient management and care. Our main objective is to evaluate the correlation of EDN in urine, blood and esophageal brushings with the eosinophilic infiltrate counted on esophageal biopsies in patients undergoing upper GI endoscopy at Trousseau Hospital for suspected eosinophilic esophagitis, or as part of the re-evaluation of known eosinophilic esophagitis under treatment.\n\nFinally, esophageal and salivary dysbiosis has been described in eosinophilic esophagitis without direct evidence of its influence on esophageal inflammation and disease. Our secondary objective is to study the esophageal, salivary and fecal microbiota in these same patients in order to describe the composition, alpha and beta-diversity of bacterial and mycological flora between patients and controls, as well as their association with pathology, and to propose possible alternative therapies aimed at modulating the esophageal and\u002For salivary microbiota in the management of eosinophilic esophagitis.\n\nThis study will be carried out on a cohort of pediatric patients followed up in the pediatric nutrition and gastroenterology department of the Trousseau-APHP hospital and hospitalized for upper GI endoscopy, either as part of a suspected case of eosinophilic esophagitis, or during follow-up of a previously known case of eosinophilic esophagitis. Blood, urine, stool, saliva, 4 additional esophageal biopsies and esophageal brushings were collected on the day of the digestive endoscopy. Depending on the eosinophilic densitý on the biopsies, subjects will be classified into either the \"patient with active eosinophilic esophagitis\" group, the \"patient with eosinophilic esophagitis in remission\" group, or the \"control without eosinophilic esophagitis\" group. The investigator aim to include 60 patients undergoing upper GI endoscopy, at least half of whoḿ will have active or remitting eosinophilic esophagitis.\n\nFurthermore, the study of the immunological, allergological and metabolomic signature of this disease is essential to enable the identification of new biomarkers to guide the creation of models combining several biomarkers predictive of eosinophilic density on esophageal biopsies. In a second step, the concentration of a panel of cytokines in blood and esophageal biopsies, the allergic sensitization profile in blood and esophageal biopsies, and an untargeted description of esophageal metabolomics will be compared between groups. In terms of clinical prospects, the investigator plan to develop a patient follow-up strategy based on the biomarkers studied, which is better adapted to clinical practice, better tolerated by patients and less costly than repeated endoscopies with esophageal biopsies.",[29],[29,470,471,472,473],"Eosinophil-derived neurotoxin","Gastrointestinal microbiome","Endoscopy, digestive system","Hypersensitivity","2025-08-25",{"date":476,"type":36},"2025-09-02",{"date":478,"type":36},"2024-04-19",{"date":480,"type":22},"2026-04",{"name":482,"class":123},"Assistance Publique - Hôpitaux de Paris",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":491,"targetDuration":95,"studyType":69,"phases":4,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":85},"100550151","prospective-registry-of-eosinophilic-esophagitis-100550151","NCT06443346","Prospective Registry of EoSinophilic esOphagitis","Prospective Registry of EoSinophilic esOphagitis (PRESO)","PRESO","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study.\n2. The medical product is the standard of care for the patient or the participant is taking the medicinal product according to clinical practice\n3. Being diagnosed with EoE as per guidelines of the disease\n\nExclusion Criteria:\n\n1. No clear diagnosis of EoE\n2. Not willing to provide informed consent to the inclusion in the registry",{"count":492,"type":22},1000,"This is a prospective registry of all the Eosinophilic Esophagitis (EoE) patients referred to the third level referral centre of San Raffaele Scientific Institute",[29],"2025-07-28",{"date":497,"type":36},"2025-07-30",{"date":499,"type":36},"2024-06-01",{"date":501,"type":22},"2044-12-31",{"name":268,"class":123},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":85},"100495418","an-intervention-study-to-improve-therapeutic-compliance-in-adult-patients-with-eosinophilic-esophagitis-100495418","NCT05730933","An Intervention Study to Improve Therapeutic Compliance in Adult Patients With Eosinophilic Esophagitis.","Inclusion Criteria:\n\n* Written informed consent\n* Male or female patient\n* Age \\>18 years\n* Previous diagnosis of EoE, confirmed by histopathology, with the presence of \\>15 eosinophilic granulocytes per high power field (hpf) in esophageal biopsies\n* Current maintenance treatment for EoE with a PPI or swallowed topical corticosteroids or about to start with these maintenance medications as decided during regular clinical practice\n\nExclusion Criteria:\n\n* Severe and clinically unstable concomitant disease that may interfere with the subject's ability to participate in the study\n* Receive investigational treatment during the study\n* Dilation of esophagus required\n* Insufficient Dutch or English language skills to understand patient information leaflets",{"count":510,"type":22},72,[25],"In many chronic conditions adherence to long-term treatment is a challenge, also for patients with eosinophilic esophagitis. Interventions, such as behavioral, educational and reminder interventions might improve treatment adherence. With this trial the investigators want to assess the effects of additional education in combination with more frequent follow up and patient reminders on adherence to treatment in adult patients with eosinophilic esophagitis.",[29],[421,515,516,517],"maintenance treatment","compliance","intervention","2025-05-28",{"date":520,"type":36},"2025-05-31",{"date":522,"type":36},"2023-04-12",{"date":524,"type":22},"2025-12",{"name":526,"class":123},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":132,"enrollmentInfo":534,"targetDuration":536,"studyType":69,"phases":4,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":146},"100592319","eosinophilic-esophagitis-towards-improved-management-100592319","NCT06991881","Eosinophilic Esophagitis: Towards Improved Management","EoStim","Inclusion Criteria:\n\n* a diagnosis of eosinophilic esophagitis\n* suspected but not yet confirmed eosinophilic esophagitis\n\nExclusion Criteria:\n\n* chronic severe conditions that preclude general anaestesia\n* lack of consent",{"count":535,"type":22},80,"15 Months","The current project aims to improve the care for children and adolescents with eosinophilic esophagitis in a collaborative effort involving pediatric units at Oslo Unversity Hospital and Helse Bergen, Norway. Existing and new non-invasive biomarkers will be explored systematically, aiming to reduce the number of endoscopies and time on restricted diet.",[29],"2025-05-27",{"date":518,"type":36},{"date":542,"type":36},"2023-10-31",{"date":544,"type":22},"2025-12-31",{"name":546,"class":123},"Oslo University Hospital",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":553,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":85},"100453134","tolerability-of-goat-milk-protein-in-eosinophilic-esophagitis-patients-with-cow-milk-protein-trigger-100453134","NCT05180578","Tolerability of Goat Milk Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger","Inclusion Criteria:\n\n* All patients diagnosed with EoE age ≤ 17.5 years at inclusion who were confirmed to have cow's milk as a trigger by demonstrating improvement during elimination and histologic relapse following reintroduction.\n* Verified histologic remission on milk-free diet on endoscopy prior to intervention\n* Proton-pump inhibitors may be used if treatment is maintained at the same dose from the screening endoscopy throughout the trial period, and was used at the time that milk was demonstrated to be the triggering food.\n* Ability to consent to enrollment in the trial - legal guardians with joint consent for patients \\>10 years.\n\nExclusion Criteria:\n\n* Patients with clinical IgE-mediated milk allergy.\n* Provisional exclusion: patients without a known IgE-mediated allergic reaction to milk who have a positive RAST (as per local reference range) or positive skin-prick test for cow milk or goat milk must be assessed by a certified allergist\u002Fimmunologist and cleared for the trial by a supervised goat milk challenge.\n* Use of inhaled corticosteroids for more than 5 days per month during the trial period.",{"count":554,"type":22},20,[25],"Eosinophilic esophagitis (EoE) is a chronic immune mediated disease characterized by eosinophilic infiltration in esophageal epithelium and resulting in esophageal dysfunction.\n\nWhile the exact pathogenesis is yet to be elucidated, EoE is considered an atopic disease. This classification is in part due to the inflammatory infiltrate of eosinophils, basophils and T-cells producing Th2 cytokines, yet it may also be triggered by environmental allergens. In addition, the rates of atopy are approximately 3 times higher in patients with EoE than in the general population. Furthermore, and most convincing, EoE is successfully managed with dietary exclusion of triggering groups in both pediatric and adult patients, further confirming the atopic nature of the disease.\n\nThe most frequent dietary trigger for EoE is milk, but there is limited data on the cross-reactivity of milk from other species. Guidelines addressing the diagnosis and treatment of EoE in both children and adults have not addressed the use of non-bovine milk in patients with cow's milk triggered EoE.\n\nRestrictive diets are often challenging for patients and contribute to a reduced quality of life. Our own, anecdotal experience in two patients with milk triggered EoE who requested to introduce goat's milk into the patients' diet were that reintroduction did not trigger a clinical or histological flare of EoE. These cases of successful introduction of non-bovine milk introduces the possibility that a milk-free diet need not necessarily be exclusive of all species.\n\nThe aim of this study is to assess tolerability and safety of goat's milk in patients with EoE in whom cow's milk has been confirmed to be a trigger food for their disease.",[29],[29,391],"2025-05-19",{"date":561,"type":36},"2025-05-22",{"date":563,"type":36},"2020-11-12",{"date":565,"type":22},"2025-10",{"name":567,"class":123},"Shaare Zedek Medical Center",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":349,"maxAge":323,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":589,"locationsCount":85},"100570295","phase-2-dupilumab-versus-topical-corticosteroid-effectiveness---comparison-in-the-treatment-of-stenotic-eoe-100570295","NCT06705387","Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE","DeTECTS: Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE","DeTECTS","Inclusion Criteria:\n\n* Seen at CHCO for clinical care.\n* Age 12 - 25 years old inclusive\n* Weight ≥40 kg at the time of screening visit\n* Confirmed EoE as diagnosed by biopsy with eosinophils ≥15 eosinophils\u002Fhpf in at least 2 esophageal regions at screening endoscopy\n* Report of an average of at least 2 episodes of dysphagia per week in the 4 weeks prior to screening.\n* Evidence of fibrostenotic features at time of screening endoscopy (grade 2 or 3 esophageal rings, stricture, delayed passage of barium tablet on fluoroscopy, and\u002For distensibility ≤15mm)\n\nExclusion Criteria:\n\n* Esophageal dilation performed at index endoscopy\n* Patients with stricture undergoing dilation at index endoscopy may be rescreened if they meet all other eligibility criteria.\n* Patients with acute food impaction will not be enrolled at their therapeutic endoscopy but are eligible for enrollment subsequently if they meet all other eligibility criteria.\n* Eligible patients on current STCs can be enrolled but need to be on stable dosing less than or equal to 440 mcg two times daily fluticasone equivalent for 3 months prior to enrollment.\n* Patients who have received dupilumab in the past 12 months for any indication are excluded.\n* Diet restrictions and PPI use must stay unchanged in the 8 weeks prior to index endoscopy and through the study period.\n* Patients with a fasting morning cortisol \\\u003C5 within 2 months of screening will not be enrolled. If repeat cortisol levels are normal, patients can be reconsented.\n* Known other esophageal disease or esophageal injury (e.g. achalasia, tracheoesophageal fistula, congenital stricture, caustic injury, history of esophageal surgery), inflammatory bowel disease, liver disease, connective tissue disorder, or bleeding disorder.\n* Patients with a known gelatin allergy will be excluded from EST collection.",{"count":510,"type":22},[179],"The goal of this clinical trial is to \\[primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc.\\] in \\[describe participant population\u002Fprimary condition; could include any of the following: sex\u002Fgender, age groups, healthy volunteers\\]. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nDoes dupilumab or swallowed topical fluticasone improve the diameter of the esophagus more? Does dupilumab or swallowed topical fluticasone reduce inflammation in the esophagus more? Are comparative effective clinical trials feasible in this patient population?\n\nResearchers will compare dupilumab 300 mg weekly compared to swallowed fluticasone to see if there is a difference in treatment response.\n\nParticipants will be asked to:\n\n* Be randomized to either dupilumab sq weekly or swallowed topical fluticasone twice daily.\n* Participate in 8 study visits over 52 weeks\n* Complete questionnaires\n* Have an endoscopy with biopsies and EndoFLIP measurements.\n* Swallow an Esophageal String Test",[29],[581,582],"Dupilumab","Fluticasone","2025-03-13",{"date":585,"type":36},"2025-03-14",{"date":587,"type":36},"2024-12-23",{"date":238,"type":22},{"name":590,"class":123},"University of Colorado, Denver",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":599,"targetDuration":326,"studyType":69,"phases":4,"briefSummary":601,"conditions":602,"keywords":608,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":85},"100412651","a-registry-for-the-food-allergy-community-100412651","NCT04653324","A Registry for the Food Allergy Community","The FARE Patient Registry: A Registry for the Food Allergy Community","FPR","Inclusion Criteria:\n\n* Individuals with diagnosed food allergy\n\nExclusion Criteria:\n\n* Individuals without food allergy",{"count":600,"type":22},23000,"The FARE Patient Registry will serve as a prospective, observational food allergy reporting system that stores detailed health and other basic information about patients' real-world experiences with food allergies, to encourage open sharing of de-identified data and participation in clinical trials. The FARE Patient Registry intends to make and support scientific discoveries by enabling the food allergy community to participate directly in research.",[603,604,29,605,606,607],"Food Hypersensitivity","Anaphylaxis","Food Sensitivity","Food Intolerance","Food Allergy in Infants",[609],"food allergy","2025-03-10",{"date":612,"type":36},"2025-03-12",{"date":614,"type":36},"2017-08-24",{"date":616,"type":22},"2027-08",{"name":618,"class":123},"Food Allergy Research & Education"]